Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2002 February; 3(4): 7–16.
Published online 2002 August 16. doi:  10.1208/pt030428
PMCID: PMC2751343

Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug


The purpose of this study was to determine if aerosol delivery of drug loaded microparticles to lungs infected withMycobacterium tuberculosis may be achieved by predicting dispersion of dry powders through knowledge of particle surface properties. Particle sizes of rifampicin-loaded poly(lactide-co-glycolide) microparticles (R-PLGA), rifampicin alone, and lactose and maltodextrin carrier particles (bulk and 75-125-μm sieved fractions) were determined by electron microscopy for the projected area diameter (Dp) and laser diffraction for the volume diameter (Dv). Surface energies (Y) of R-PLGA, rifampicin alone, lactose, and maltodextrin were obtained by inverse phase gas chromatography, surface areas (Sa) by N2 adsorption, and cohesive energy densities by calculation. Particle dispersion was evaluated (Andersen nonviable impactor) for 10% blends of R-PLGA and rifampicin alone with bulk and sieved fractions of the carriers. Dp for R-PLGA and rifampicin alone was 3.02 and 2.83 μm, respectively. Dv was 13±1 and 2±1 μm for R-PLGA and rifampicin alone, respectively, indicating that R-PLGA was more aggregated. This was evident in Y of 35±1 and 19±6 mJ/m2 for R-PLGA and rifampicin alone. Dp for lactose and maltodextrin (sieved and bulk) was approximately 40 mm. Bulk maltodextrin (Dv=119±6 mm) was more aggregated than bulk lactose (Dv=54±2 mm). This was a result of the higher Sa for maltodextrin (0.54 m2/g) than for lactose (0.21 m2/g). The Y of bulk lactose and maltodextrin was 40±4 and 60±6 mJ/m2 and of sieved lactose and maltodextrin was 39±1 and 50±1 mJ/m2. Impaction studies yielded higher fine particle fractions of R-PLGA from sieved lactose, 13%±3%, than from sieved maltodextrin, 7%±1%, at 90 L/min. An expression, based on these data, is proposed as a predictor of drug dispersion from carrier particles.

Delivery of dry powder formulations can be achieved by characterizing particle surfaces and predicting impact on dispersion.

Full Text

The Full Text of this article is available as a PDF (607K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. World Health Organization. World Health Organization Report. Geneva, Switzerland; 2001.
2. Comstock GW, Cauthen GM. Epidemiology of tuberculosis. In: Reichman LB, Hershfield ES, editors. Tuberculosis: A Comprehensive International Approach. New York, NY: Marcel Dekker; 1993. pp. 23–48.
3. Grosset JH. Bacteriology of tuberculosis. In: Reichman LB, Hershfield ES, editors. Tuberculosis: A Comprehensive International Approach. New York, NY: Marcel Dekker; 1993. pp. 49–74.
4. O Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17(8):955–961. doi: 10.1023/A:1007527204887. [PubMed] [Cross Ref]
5. Suarez S, O Hara P, Kazantseva M, et al. Airway delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48:431–434. doi: 10.1093/jac/48.3.431. [PubMed] [Cross Ref]
6. Suarez S, O Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18(9):1315–1319. doi: 10.1023/A:1013094112861. [PubMed] [Cross Ref]
7. Ashurst I, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today. 2000;3(7):246–256. doi: 10.1016/S1461-5347(00)00275-3. [PubMed] [Cross Ref]
8. Montreal Protocol on Substances That Deplete Ozone Layer. Washington, DC: US Government Printing Office; 1987. pp. 26–26.
9. Dunbar CA, Hickey AJ, Holzner P. Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols. KONA. 1998;16:7–46.
10. Lowell S. Introduction to Powder Surface Area. New York, NY: John Wiley & Sons; 1979.
11. Fowkes FM. Attractive forces at interfaces. J Ind Eng Chem. 1964;56:40–52. doi: 10.1021/ie50660a008. [Cross Ref]
12. Chu B. Molecular Forces. New York, NY: John Wiley & Sons; 1967.
13. Hancock BC, York P, Rowe RC. The use of solubility parameters in pharmaceutical dosage form design. Int J Pharm. 1997;148:1–21. doi: 10.1016/S0378-5173(96)04828-4. [Cross Ref]
14. Allen T. Particle Size Measurement. London, England: Chapman and Hall; 1968.
15. Schultz J, Lavielle L, Martin C. The role of the interface in carbon fibre-epoxy composites. J Adhes. 1987;23:45–60. doi: 10.1080/00218468708080469. [Cross Ref]
16. Ticehurst MD, Rowe RC, York P. Determination of the surface properties of two batches of salbutamol sulphate by inverse gas chromatography. Int J Pharm. 1994;111:241–249. doi: 10.1016/0378-5173(94)90347-6. [Cross Ref]
17. Dove JW, Buckton G, Doherty C. A comparison of two contact angle measurement methods and inverse gas chromatography to assess the surface energies of theophylline and caffeine. Int J Pharm. 1996;138:199–206. doi: 10.1016/0378-5173(96)04535-8. [Cross Ref]
18. Mohammad HAH, Fell JT. Contact angles of powder mixtures consisting of spherical particles. Int J Pharm. 1982;11:149–154. doi: 10.1016/0378-5173(82)90050-3. [Cross Ref]
19. Newell HE, Buckton G, Butler DA, Thielmann F, Williams DR. The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallisation. Int J Pharm. 2001;217(1–2):45–56. doi: 10.1016/S0378-5173(01)00589-0. [PubMed] [Cross Ref]
20. Conder JR, Young CL. Physicochemical Measurement by Gas Chromatography. New York, NY: John Wiley & Sons; 1979.
21. Fedors RF. A method for estimating both the solubility parameters and molar volumes of liquids. Polymer Eng Sci. 1974;14:147–154. doi: 10.1002/pen.760140211. [Cross Ref]
22. Van Krevelen DW. Properties of Polymers: Their Estimation and Correlation With Chemical Structure. New York, NY: Elsevier Scientific; 1976.
23. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med. 1993;6(2):99–110. doi: 10.1089/jam.1993.6.99. [PubMed] [Cross Ref]
24. Pelizza G, Nebuloni M, Ferrari P, Gallo GG. Polymorphism of rifampicin. Farmaco Edizione Scientifica. 1977;32(7):471–481. [PubMed]
25. Riddle FLJ, Fowkes FM. Spectral shifts in acid-base chemistry, I: Van der Waals contributions to acceptor numbers. J Am Chem Soc. 1990;112(9):3259–3264. doi: 10.1021/ja00165a001. [Cross Ref]
26. Martin A. Physical Pharmacy. 4th ed. Baltimore, MD: Williams & Wilkins; 1993.
27. Concessio NM, Van Oort MM, Knowles MR, Hickey AJ. Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm Res. 1999;16(6):828–834. doi: 10.1023/A:1018865717374. [PubMed] [Cross Ref]
28. Handbook of Pharmaceutical Excipients. Washington, DC: American Pharmaceutical Association; 1986.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists